



Attorney Docket No. 1124574604

TECH CENTER
600/2900

RECEIVED
PATENT
03 2002

3/3
10
6-1182

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Harlan W. Waksal

Application No.: 09/840,146

Filing Date: April 24, 2001

Examiner: Hunt, Jennifer

Art Unit: 1642

For: Treatment of Refractory
Human Tumors with
Epidermal Growth Factor
Receptor Antagonists

SECOND PRELIMINARY AMENDMENT

U.S. Patent and Trademark Office
P.O. Box 2327
Arlington, VA 22202

Dear Sir:

Prior to examination of the present application, please enter the following amendments
and consider the following remarks.

AMENDMENTS

In the Specification:

At page 7, ll. 7-11, please replace the original paragraph with the following
paragraph:

B1

The growth of refractory tumors is sufficiently inhibited in the patient to prevent or reduce the progression of the cancer (i.e. growth, invasiveness, metastasis, and/or recurrence). The EGFR antagonists of the present invention can be cytostatic or inhibit the growth of the refractory tumor. Preferably, the EGFR antagonist is cytolytic or destroys the tumor.

12/03/2001 5DENE051 00000018 110300 09374025

01 75:00 513.00 JH